Qiagen N.V. (QGEN)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 1,870 | 2,252 | 2,142 | 1,965 | 1,978 | 2,090 | 2,100 | 2,136 |
| Operating profit | $m | 520 | 532 | ||||||
| Net profit | $m | 359 | 513 | 423 | 341 | 84 | 425 | 409 | 501 |
| EPS reported | $ | 2.04 | 1.95 | ||||||
| Operating cashflow per share | $ | 3.15 | 3.17 | ||||||
| Capex per share | $ | 0.97 | 1.00 | ||||||
| FCF per share | $ | 2.18 | 2.17 | ||||||
| Free cash flow | $m | 453 | 448 | ||||||
| Net debt | $m | 556 | 850 | ||||||
| Book value equity | $m | 3,778 | 3,358 | ||||||
| Book value per share | $ | 18.17 | 16.16 | ||||||
| Number of shares | m | 207.94 | 207.83 | ||||||
| DPS (TTM paid) | $ | 2.54 | 2.64 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 23.21 | 22.66 | ||||||
| P/B LTM | x | 2.61 | 2.93 | ||||||
| P/S LTM | x | 4.71 | 4.69 | ||||||
| P/FCF LTM | x | 21.72 | 21.99 | ||||||
| EV/EBITDA LTM | x | 14.86 | 14.48 | ||||||
| EV/Sales LTM | x | 5.10 | 4.63 | ||||||
| Earnings Yield LTM | % | +4.31% | +4.41% | ||||||
| FCF Yield | % | +4.60% | +4.55% | ||||||
| Quality | |||||||||
| ROE | % | +11.25% | +11.60% | ||||||
| ROIC | % | +7.80% | +8.86% | ||||||
| Operating margin | % | +24.90% | +25.33% | ||||||
| Gross margin | % | +61.79% | +61.82% | ||||||
| FCF/Sales | % | +21.69% | +21.32% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +436.84% | +413.16% | ||||||
| Sales Growth YoY | % | +5.65% | +6.17% | ||||||
| Net Income Growth YoY | % | +408.28% | +389.67% | ||||||
| FCF Growth | % | -10.49% | -11.59% | ||||||
| Operating Profit Growth | % | +432.50% | +444.55% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +0.55% | +6.15% | ||||||
| Dividend Growth | % | -80.71% | +103.70% | ||||||
| Payout Ratio | % | +12.79% | +13.20% | ||||||
| FCF/Debt | x | 0.27 | 0.27 | ||||||
| Net Debt/EBITDA | x | 1.14 | 1.19 | ||||||
| EBIT/Net interest | x | 15.65 | 13.49 | ||||||
| Net debt/market cap | % | +16.81% | +18.55% | ||||||
| Net debt/Equity | x | 0.15 | 0.25 | ||||||
| Gross debt/equity | x | 0.44 | 0.49 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free